Sarah Sammons, MD, is a medical oncologist and clinical investigator in the Breast Oncology Center, and an associate director of the Metastatic Breast Cancer Program at Dana-Farber Cancer Institute.
A Closer Look at T-DXd in HER2-Positive Breast Cancer
Sarah Sammons, MD, provides an overview of the DESTINY-Breast03 trial.